{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:47:09Z","timestamp":1773456429436,"version":"3.50.1"},"reference-count":99,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T00:00:00Z","timestamp":1421798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Astellas"},{"name":"Belgian Federal Government","award":["IUAP P7\/13"],"award-info":[{"award-number":["IUAP P7\/13"]}]},{"name":"Research Council of the KU Leuven (PF-TRPLe)"},{"name":"Research Foundation - Flanders","award":["G.0825.11"],"award-info":[{"award-number":["G.0825.11"]}]},{"name":"TRUST FP 7 programme"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2015,5]]},"abstract":"\n Transient receptor potential (\n TRP<\/jats:styled-content>\n ) channels belong to the most intensely pursued drug targets of the last decade. These ion channels are considered promising targets for the treatment of pain, hypersensitivity disorders and lower urinary tract symptoms (\n LUTS<\/jats:styled-content>\n ). The aim of the present review is to discuss to what extent\n TRP<\/jats:styled-content>\n channels have adhered to their promise as new pharmacological targets in the lower urinary tract (\n LUT<\/jats:styled-content>\n ) and to outline the challenges that lie ahead.\n \n \n \n TRP<\/jats:styled-content>\n vanilloid 1 (\n TRPV1<\/jats:styled-content>\n ) agonists have proven their efficacy in the treatment of neurogenic detrusor overactivity (\n DO<\/jats:styled-content>\n ), albeit at the expense of prolonged adverse effects as pelvic \u2018burning\u2019 pain, sensory urgency and haematuria.\n <\/jats:p>\n <\/jats:list-item>\n \n \n TRPV1<\/jats:styled-content>\n antagonists have been very successful in preclinical studies to treat pain and\n DO<\/jats:styled-content>\n . However, clinical trials with the first generation\n TRPV1<\/jats:styled-content>\n antagonists were terminated early due to hyperthermia, a serious, on\u2010target, side\u2010effect.\n <\/jats:p>\n <\/jats:list-item>\n \n \n TRP<\/jats:styled-content>\n vanilloid 4 (\n TRPV4<\/jats:styled-content>\n ),\n TRP<\/jats:styled-content>\n ankyrin 1 (\n TRPA1<\/jats:styled-content>\n ) and\n TRP<\/jats:styled-content>\n melastatin 8 (\n TRPM8<\/jats:styled-content>\n ) have important sensory functions in the\n LUT<\/jats:styled-content>\n . Antagonists of these channels have shown their potential in pre\u2010clinical studies of\n LUT<\/jats:styled-content>\n dysfunction and are awaiting clinical validation.\n <\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>","DOI":"10.1111\/bju.12876","type":"journal-article","created":{"date-parts":[[2014,7,25]],"date-time":"2014-07-25T05:03:48Z","timestamp":1406264628000},"page":"686-697","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Transient receptor potential channel modulators as pharmacological treatments for lower urinary tract symptoms (\n LUTS<\/scp>\n ): myth or reality?"],"prefix":"10.1111","volume":"115","author":[{"given":"Yves","family":"Deruyver","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Urology Department of Development and Regeneration KU Leuven Leuven Belgium"},{"name":"University Hospitals Leuven Leuven Belgium"},{"name":"TRP Research Platform Leuven (TRPLe) Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Voets","sequence":"additional","affiliation":[{"name":"Laboratory for Ion Channel Research Department of Molecular Cell Biology KU Leuven Leuven Belgium"},{"name":"TRP Research Platform Leuven (TRPLe) Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"De Ridder","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Urology Department of Development and Regeneration KU Leuven Leuven Belgium"},{"name":"University Hospitals Leuven Leuven Belgium"},{"name":"TRP Research Platform Leuven (TRPLe) Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter","family":"Everaerts","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Urology Department of Development and Regeneration KU Leuven Leuven Belgium"},{"name":"TRP Research Platform Leuven (TRPLe) Leuven Belgium"},{"name":"Royal Melbourne Hospital Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,1,21]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2007.02.002"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.12.060"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/39807"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07493.x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(01)00496-1"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00349.2010"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02190.x"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.231243698"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.90718.2008"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.08.022"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.4161\/chan.3.3.8555"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00599.2009"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1369\/jhc.2008.951962"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.020206"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.01.048"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00127.2013"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.6451-10.2011"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-008-0391-7"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn902"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2007.139147"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2657-04.2004"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.05.016"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2008.03.020"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.11.046"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2003.04722.x"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1838(92)90031-B"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20511"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1838(90)90105-R"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresrev.2008.12.006"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)38701-3"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6777(1998)17:5<513::AID-NAU7>3.0.CO;2-G"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.sc.3100505"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20296"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/003655999750016078"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/10790268.2003.11753706"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.04.012"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000100385.93801.d4"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65183-X"},{"issue":"1","key":"e_1_2_10_40_1","first-page":"29","article-title":"The treatment of overactive bladder syndrome refractory to antimuscarinic therapy","volume":"2","author":"Lim EK","year":"2008","journal-title":"Incont Pelvic Floor Dysfunc"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(04)90411-3"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1159\/000020004"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/10790268.2008.11760706"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65669-6"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000154631.92150.ef"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.5213\/inj.2012.16.1.41"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.03.087"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20300"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-7-9"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.08.121"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2011.09.005"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.09.055"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.03.085"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3456"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04040.x"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.03.003"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature06191"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3181a915e7"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000000236"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000000088"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbiomolbio.2009.10.002"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31766"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.04.107"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.139295"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.21212"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1005333107"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00008.2014"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.512"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2012.711320"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11300.x"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.134551"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004276"},{"key":"e_1_2_10_73_1","unstructured":"ClinicalTrials.gov.A First Time in Human Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients: GlaxoSmithKline 2014. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02119260?term=TRPV4&rank=1. Accessed May 2014"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-34891-7_20"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-6-6"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2011.05.006"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000134880.55119.cf"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.10.006"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.11.137"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.90269.2008"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-1716.1991.tb09037.x"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurpsyc.1957.02330400013002"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2221-07.2007"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M605213200"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000170235.22776.1a"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22325"},{"key":"e_1_2_10_87_1","unstructured":"KawamuraK ShishidoY OhmiM Inventors; Raqualia Pharma Inc. Original Assignee.Sulfamoyl Benzoic Acid Heterobicyclic Derivatives as trpm8 Antagonists patent US 20130210858 A1. 15 August2013"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5606-11.2012"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-34891-7_21"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.10.024"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.06.1110"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2006.04.003"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.12.093"},{"key":"e_1_2_10_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4125"},{"key":"e_1_2_10_95_1","first-page":"572","article-title":"The bladder\u2010cooling reflex is a local phenomenon, mediated by TRPA1","volume":"32","author":"Uvin P","year":"2013","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_10_96_1","unstructured":"EU Clinical Trials Register.A Phase 2a Multi\u2010Centre Randomised Double\u2010Blind Parallel Group Placebo\u2010Controlled Study to Evaluate Efficacy Safety and Tolerability of Inhaled GRC 17536 Administered for 4 Weeks in Patients with refractory chronic cough (internet) (Place unknown): Glenmark Pharmaceuticals SA 2013. Available at:https:\/\/www.clinicaltrialsregister.eu\/ctr\u2010search\/search?query=2013\u2010002728\u201017. Accessed May 2014"},{"key":"e_1_2_10_97_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00535.2010"},{"key":"e_1_2_10_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.03.023"},{"key":"e_1_2_10_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.10.016"},{"key":"e_1_2_10_100_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00417.2012"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.12876","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.12876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:46:51Z","timestamp":1761745611000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.12876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,21]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1111\/bju.12876"],"URL":"https:\/\/doi.org\/10.1111\/bju.12876","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,21]]},"assertion":[{"value":"2015-01-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}